

BHARATHIDASAN UNIVERSITY

Tiruchirappalli- 620024, Tamil Nadu, India

Programme: M.Sc., Biomedical science

Course Title : Cancer Biology

Course Code: 18BMS59C16

Unit-IV

TOPIC: Tumor Staging & Grading Dr. G.MATHAN


Professor

Department of Biomedical Science

Types of Cancer

- Cancer can affect almost any tissue type in the body.
 - Lung cancer
 - Skin Cancer
 - Liver Cancer
 - Breast Cancer
 - Cervical Cancer
 - Prostate Cancer





Tumor Classification

- Anatomical Site
- Cell of Origin
- Biological behavior



■ There are a large variety of tumors because tumors can originate from any cell type.


Types of Differentiation

■ 1. Well differentiated

- closely resemble the cell of origin
- easily classified by histology

2. <u>Undifferentiated</u>

- do not resemble normal cells
- more difficult to classify
- also called "anaplastic"



Cancer terminology

- Classification by tissue type:
- carcinoma
 epithelial cell
 90% of all tumours
 derived from ectoderm
 (mostly) or endoderm (some)
- sarcomaconnective tissue2% of all tumoursderived from mesoderm
- leukaemiacirculatory or lymphatic8% of all tumoursderived from mesoderm

- Classification by the type of cells:
- Adenomatous cells ductal or glandular cells
- Squamous cells flat cells
- Myeloidblood cell
- Lymphoidlymphocytes or macrophages

Epidemiology

- The study of disease incidence.
- Statistical databases identifying patterns of cancer occurrence.
- Researchers use this information and determine incidence of cancer in a general population.
- Use factors such as age, gender, race, geographical location.

Staging-

Defining Tumor Size and Extension at Point of Diagnosis

- Reason it's important
 - -provides a means of communication about tumors
 - -provides a basis for comparison between tumors
 - -helps in determining best treatment
 - -Aids in predicting prognosis
 - -provides a means for continuing research

Surveillance, Epidemiology and End Results (SEER) Program


- As technologies advance staging systems change
- TNM- is the current staging system used by the International Union Against Cancer and American Joint Committee on Cancer
- Extent of Disease (EOD)
- Summary Stage (SS)- General Staging, California Staging, and SEER Staging.-combination of the most precise clinical and pathological documentation of the extent of disease

Extent of Disease (EOD)


- The EOD coding scheme consists of a ten-digit code.
- Three digits for the size and/or involvement of the primary tumor,
- Two for the extension of the tumor,
- One more as a general code for lymph node involvement.
- Four more digits are used after these six: two for the number of pathologically positive regional lymph nodes and two more for the number of regional lymph nodes that are pathologically examined.

How Cancer Spreads

- Local invasion
- Direct extension
- Lymphatic metastases
- Blood-borne metastases
- Intra-cavitary



© Fleshandbones.com Henry & Thompson: Clinical Surgery




© Fleshandbones.com Henry & Thompson: Clinical Surgery

Summary Staging

- 0 in situ
- 1 localized
- 2 regional by direct extension only
- 3 regional lymph nodes involved only
- 4 regional by both direct extension and lymph node involvement
- 5 regional, NOS (not otherwise specified)
- 7 distant site(s)/node(s) involved
- 9 unknown (unstaged, unknown or unspecified)

What is TNM Staging?

- Developed by physicians (AJCC)
- Uniform staging system to determine treatment, prognosis & end results
- \Box T = Tumor
- N = Nodes
- M = Metastasis
- Group Stage = summary of TNM



Pierre Denoix

TNM staging system for all solid tumours was devised by Pierre Denoix between 1943 and 1952

TNM Staging T=Tumor, N=Node, M=Metastasis

- T-size and extent of primary tumor is assigned a number 0-4
 - T0(zero)-no evidence of disease
 - T1-confined to organ of origin, not invading other tissue
 - T2-Deep extension into nearby structures or tissues
 - T3-Confined to region of origin, rather than organ.
 - T4-massive lesion extending into other tissues and organs causing fistulas in hollow organs and making a sinus in solid organs.

N=node Designates the status of lymph nodes and the extent of lymph node involvement

- 0-4 designates the status of lymph nodes and the extent of lymph node involvement.
- N0 (zero)- no positive nodes are present.
- N1-palpable movable nodes in first drainage station the same site of the tumor (1-2 cm).
- N2-larger nodes 3-5 cm invading into capsule.
- N3-Nodes are fixed to bone, muscle, skin, or blood vessels usually 6 cm in size.
- N4- Positive nodes at more distant nodal sites beyond first station.

M=Metastasis, the presence and/or extent of.

- M0(zero) –no metastasis
- M1- One metastasis in one organ or site
- M2-multiple metastatic lesions in one organ system.
- M3- Multiple organs involved with little or no impairment of function.
- M4- Multiple organs with impairment of function.
- MX unable to access
- Large numbers are more advanced

Many more staging systems, but TNM is widely used.

Common Metastatic Sites of Primary Tumors (Table 1 -7)

Primary Site	Metastatic Site
Lung	Liver, adrenal glands, bone, brain
Breast	Lungs, bone, brain
Stomach	Liver
Anus	Liver and lungs
Bladder	Lungs, bone, liver
Prostate	Bone, liver, lungs
Uterine Cervix	Lungs, bone, liver

Group Stage

- Is the general reference point of comparison
- Tis = Stage 0
- Stage I, Stage II, Stage III, Stage IV


Descriptors


	h	Indication	
Suffix	m	Presence of multiple primary T	pT(m)NM
Prefix	y	Post initial treatment (staging after preop treatment)	ycTNM or ypTNM
	r	Recurrent tumor after a disease free interval	rTNM
	a	Autopsy	aTNM

Clinical, Pathologic, Collaborative Staging

- Clinical (cT, cN, cM)
 - Before initiation of primary treatment
 - Important in deciding primary treatment
- Pathologic (pT, pN, pM)
 - From resected tissues
- Collaborative Stage (CS) allows combined pathological and clinical "mixed" or "best" stages to be captured.
 - Implemented by the cancer registries
 - Stage derived through computer algorithms

Staging







Breast profile:

A ducts,

B lobules,

C dilated section of duct to hold milk

D nipple,

E fat,


F pectoralis major muscle, **G** chest wall/rib cage


Enlargement:


A normal duct cells,

B ductal cancer cells breaking through the basement membrane

C basement membrane









T4a Extension to chest wall, not including pectoralis muscle

T4b ulceration of the skin of the breast, or satellite skin nodules confined to the same breast

T4c Both T4a and T4b

Inflammatory carcinoma







Lymph Node Areas Adjacent to Breast Area

A- Pectoralis major muscle

B- Axillary LN: levels I **C** -Axillary LN: levels II


D- Axillary LN: levels III

E- Supraclavicular LN

F -Internal mammary LN

Breast Cancer Staging Stage I







Breast Cancer Staging Stage IIA



Stage IIA







Stage IIa may also describe cancer in the axillary lymph nodes with no evidence of a tumor in the breast

Breast Cancer Staging Stage IIB




Stage IIB






Breast Cancer Staging Stage IIIA






Breast Cancer Staging Stage IIIB, IIIC









Stage IV Breast Cancer

 Stage IV breast cancer can be any size and has spread to distant sites in the body, usually the bones, lungs or liver, or chest wall



AJCC Staging System (anatomic)



<u>T</u>	<u>N</u>	<u>M</u>	<u>Stage</u>
1	0	0	I
0-2	0-1	0	IIa
2-3	0-1	0	IIb
0-3	1-2	0	IIIa
4 or 0-1	1-2	0	IIIb
Any	3	0	IIIc
any	any	1	IV

Ovarian cancer

- Ovarian cancer: is the fifth leading cause of cancer related death and the leading cause of death from gynecological malignancies.
- Difficult to diagnose
- Late diagnosis: Stage 3 cancer of the ovary
- > 80% of Ovarian cancer present with omental metastasis
- > Screening test: CA 125 (50%) accuracy, late marker
- > Standard treatment : no change in survival rate

Scenario in India


- ✓ Massive surge in cancer cases in India
- ✓ As per WHO, 500,000 people die of cancer and
- expected to rise to 700,000 by 2015.



Different stages of ovarian cancer
































Diagram showing stage 1 ovarian cancer Copyright © CancerHelp UK

Copyright @ CancerHelp UK





Stage 3A cancer cells are in the lining of the abdomen (only seen under a microscope)

Stage 3B tumours of 2cm or smaller are in the lining of the abdomen

Stage 3C cancer is in the lymph nodes

Diagram showing stage 3A to 3C ovarian cancer Copyright © CancerHelp UK




Diagram showing stage 4 ovarian cancer Copyright © CancerHelp UK

Grade provides info about the tumors aggressiveness


- Grade is based on the degree of differentiation (histology).
- Grading can also be described as the degree of malignancy.
 - G1-Well differentiated
 - G2-Moderately well differentiated
 - G3- Poorly differentiated
 - G4- Very poorly differentiated


The degree of malignancy is determined by the proportion of poorly differentiated to well differentiated cells.

The more undifferentiated a tumor is the more likely it is to metastasize.

*Differentiation may be different throughout the tumor.

FIGURE 5: GLEASON SCORE PATTERNS





Grading & Staging

- Together, the stage and grade offer an accurate picture of the tumor and its behavior.
- This allows physicians to make better, more effective, treatment decisions

Grading

- · How abnormal the cells are
- 1, 2, 3,4
- Based on
 - Tubule formation
 - Size and shape of cells
 - Mitotic division
- Measures the likely aggressiveness of the cells


VS

Staging

- How far the cancer has spread
- I, II, III, IV
- · Based on
 - Size of tumor
 - Invasive vs non invasive
 - Spread to lymph nodes
 - Spread to other parts of the body

OTHER CLASSIFICATION

Ann Arbour → lymphomas



A = without symptoms
B = with symptoms including
unexplained weight loss
(≥10% in 6 months prior to
diagnosis), unexplained
fever, and drenching night
sweats.

Stage I	one lymph node area	
Stage II	two or more lymph node areas but confined to one side of the diaphragm	
Stage III	lymph nodes above and below the diaphragm – spleen involvement included	
Stage IV outside the lymph node areas, e.g. bone marrow, liver and other extranodal sites		

Duke's classification → colon cancer


TNM stage	Modified dukes stage	Description
TIN0M0	Α	Limited to submucosa
T2N0M	ВІ	Limited to muscularis propria
T3N0M0	B2	Transmural extension
T2N1M0	CI	T2, enlarged mesenteric nodes
T3N1M0	C2	T3, enlarged mesenteric nodes
T4	C2	Invasion of adjacent organs
Any T, MI	D	Distant metastases present


Stage A B1 B2	Features Tumor confined to the mucosa Tumor growth into muscularis propria Tumor growth through muscularis propria and serosa	5-year survival 90–95% 75–80% 60%
C1 C2 D	(full thickness) Tumor spread to 1–4 regional lymph nodes Tumor spread to more than 4 regional lymph nodes Distant metastases (liver, lung, bones)	25–30% <1%

Modified from the American Joint Committee on Cancer.TNM:Tumor node metastasis



Cuthbert Dukes





Dr. Breslow suggested measuring from the top of the granular layer to the bottom of the melanoma using an occular micrometer within the microscope. This method is highly reproducible and now widely used.

Breslow scale and Clark's level → melanoma

	k scale el of invasion)	Breslow scale (vertical thickness)	Risk for metastasis
1	Epidermis (in situ)	in situ	None
II	Invades papillary dermis	<0.75 mm	Minimal (excellent prognosis)
III	Fills the papillary dermis to papillary-reticular junction	0.75–1.5 mm	Significant/medium
IV	Invades reticular dermis	1.51-4.0 mm	High
٧	Invades subcutaneous fat/tissue	>4.0 mm	Extremely high

Types of Diagnostic Exams



Normal Chest X-ray



Lung Cancer

- Chest x-ray
- CT
- Colonoscopy
- MRI
- US

Pathology reports → biopsy, cytology





MRI of Glioblastoma Multiforme

<u>Laboratory tests</u> → blood, urine, AST/ALT, tumor markers (CA19-9, CA19-5....)

computerized tomography scan positron emission tomography (PET)

Thanks for your Attention

Acknowledgement

- ❖ The presentation is being used for educational and non-commercial purposes.
- ❖ Thanks are due to all the original contributors and entities whose pictures were used in the creation of this presentation.